

Adil I Daud

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5562689/publications.pdf>

Version: 2024-02-01

247
papers

37,561
citations

10979

71
h-index

3031

188
g-index

255
all docs

255
docs citations

255
times ranked

37023
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab versus Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2015, 372, 2521-2532.	13.9	4,838
2	Safety and Tumor Responses with Pembrolizumab (Anti-PD-1) in Melanoma. <i>New England Journal of Medicine</i> , 2013, 369, 134-144.	13.9	3,128
3	Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations. <i>New England Journal of Medicine</i> , 2012, 367, 1694-1703.	13.9	2,445
4	Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. <i>Lancet</i> , The, 2014, 384, 1109-1117.	6.3	1,588
5	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 908-918.	5.1	1,419
6	PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016, 374, 2542-2552.	13.9	1,048
7	Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). <i>Lancet</i> , The, 2017, 390, 1853-1862.	6.3	1,032
8	Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity. <i>Cancer Cell</i> , 2014, 26, 638-652.	7.7	911
9	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1600.	3.8	857
10	Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2019, 20, 1239-1251.	5.1	812
11	A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. <i>Nature Medicine</i> , 2018, 24, 1178-1191.	15.2	679
12	Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. <i>Annals of Oncology</i> , 2019, 30, 582-588.	0.6	641
13	Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN- γ and IL-12. <i>Immunity</i> , 2018, 49, 1148-1161.e7.	6.6	639
14	Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 4286-4293.	3.2	627
15	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. <i>Journal of Clinical Oncology</i> , 2016, 34, 1510-1517.	0.8	627
16	Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 5896-5903.	0.8	613
17	Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 4102-4109.	0.8	528
18	Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 2823-2830.	0.8	517

#	ARTICLE	IF	CITATIONS
19	Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. <i>Journal of Clinical Investigation</i> , 2016, 126, 3447-3452.	3.9	439
20	Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 383-390.	0.8	431
21	Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600E Mutant Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 4023-4031.	0.8	430
22	The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. <i>BMC Medical Genomics</i> , 2008, 1, 13.	0.7	425
23	Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity. <i>Cell</i> , 2019, 177, 556-571.e16.	13.5	405
24	Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. <i>Cancer Immunology Research</i> , 2017, 5, 417-424.	1.6	400
25	Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. <i>Oncogene</i> , 2002, 21, 7001-7010.	2.6	391
26	Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. <i>JAMA Dermatology</i> , 2015, 151, 1206.	2.0	385
27	Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 1668-1674.	0.8	360
28	A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. <i>Clinical Cancer Research</i> , 2002, 8, 2505-11.	3.2	339
29	Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. <i>Cancer</i> , 2016, 122, 3344-3353.	2.0	288
30	Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 693-702.	0.8	274
31	Overall Survival and Durable Responses in Patients With BRAF V600E Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. <i>Journal of Clinical Oncology</i> , 2016, 34, 871-878.	0.8	266
32	Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin. <i>Journal of Clinical Oncology</i> , 2008, 26, 5198-5203.	0.8	229
33	Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study. <i>Lancet Oncology</i> , The, 2014, 15, 954-965.	5.1	225
34	Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2018, 24, 4960-4967.	3.2	222
35	Phase I Trial of Histone Deacetylase Inhibition by Valproic Acid Followed by the Topoisomerase II Inhibitor Epirubicin in Advanced Solid Tumors: A Clinical and Translational Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 1979-1985.	0.8	205
36	Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 4015-4020.	3.3	203

#	ARTICLE	IF	CITATIONS
37	Long-Term Outcomes in Patients With <i>BRAF</i> V600E-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. <i>Journal of Clinical Oncology</i> , 2018, 36, 667-673.	0.8	196
38	Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2008, 14, 8302-8307.	3.2	193
39	Valproic Acid Alters Chromatin Structure by Regulation of Chromatin Modulation Proteins. <i>Cancer Research</i> , 2005, 65, 3815-3822.	0.4	191
40	Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. <i>European Journal of Cancer</i> , 2017, 86, 37-45.	1.3	183
41	Phenotypic and Functional Analysis of Dendritic Cells and Clinical Outcome in Patients With High-Risk Melanoma Treated With Adjuvant Granulocyte Macrophage Colony-Stimulating Factor. <i>Journal of Clinical Oncology</i> , 2008, 26, 3235-3241.	0.8	178
42	Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. <i>Journal of Cellular Biochemistry</i> , 2004, 92, 223-237.	1.2	176
43	Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With <i>BRAF</i> V600E-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor. <i>Journal of Clinical Oncology</i> , 2014, 32, 3697-3704.	0.8	173
44	Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2015, 33, 1060-1066.	0.8	161
45	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , The, 2019, 20, e378-e389.	5.1	155
46	Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. <i>British Journal of Cancer</i> , 2009, 101, 1044-1050.	2.9	150
47	Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis. <i>Science Immunology</i> , 2020, 5, .	5.6	148
48	Spectrum of Activity and Mechanism of Action of VEGF/PDGF Inhibitors. <i>Cancer Control</i> , 2007, 14, 285-294.	0.7	145
49	Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3001-3001.	0.8	140
50	An analysis of genetic heterogeneity in untreated cancers. <i>Nature Reviews Cancer</i> , 2019, 19, 639-650.	12.8	139
51	Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC. <i>Clinical Cancer Research</i> , 2009, 15, 2488-2496.	3.2	137
52	Melanoma, Version 2.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 395-407.	2.3	134
53	Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial. <i>Annals of Oncology</i> , 2017, 28, 1380-1387.	0.6	134
54	Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 5250-5260.	3.2	116

#	ARTICLE	IF	CITATIONS
55	Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer. <i>Nature Communications</i> , 2020, 11, 3584.	5.8	115
56	Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. <i>British Journal of Cancer</i> , 2018, 119, 670-674.	2.9	114
57	Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. <i>British Journal of Cancer</i> , 2017, 116, 1141-1147.	2.9	112
58	Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. <i>European Journal of Cancer</i> , 2018, 101, 236-243.	1.3	100
59	Cutaneous Melanoma: Prognostic Factors. <i>Cancer Control</i> , 2005, 12, 223-229.	0.7	98
60	Phase I Trial of Poly-<sc> </sc>-Glutamate Camptothecin (CT-2106) Administered Weekly in Patients with Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , 2007, 13, 5855-5861.	3.2	98
61	Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9503-9503.	0.8	98
62	Clonal Deletion of Tumor-Specific T Cells by Interferon- β Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. <i>Immunity</i> , 2019, 50, 477-492.e8.	6.6	93
63	Evidence for Selective Expression of Angiotensin II Receptors on Atretic Follicles in the Rat Ovary: An Autoradiographic Study*. <i>Endocrinology</i> , 1988, 122, 2727-2734.	1.4	87
64	Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 2827-2837.	3.2	86
65	Potential of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial. <i>Clinical Cancer Research</i> , 2009, 15, 2479-2487.	3.2	82
66	Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. <i>Annals of Oncology</i> , 2020, 31, 532-540.	0.6	82
67	Evaluation of Toxicity following Electrically Mediated Interleukin-12 Gene Delivery in a B16 Mouse Melanoma Model. <i>Clinical Cancer Research</i> , 2006, 12, 3177-3183.	3.2	79
68	Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 1092-1100.	3.2	78
69	Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. <i>Annals of Oncology</i> , 2015, 26, 415-421.	0.6	78
70	Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. <i>European Journal of Cancer</i> , 2016, 67, 46-54.	1.3	77
71	Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma. <i>Annals of Oncology</i> , 2015, 26, 2173-2179.	0.6	74
72	Single-cell analyses identify circulating anti-tumor CD8 T cells and markers for their enrichment. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	74

#	ARTICLE	IF	CITATIONS
73	Melanoma immunotherapy. <i>Cancer Biology and Therapy</i> , 2014, 15, 665-674.	1.5	73
74	In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1993-2000.	1.9	71
75	Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. <i>Nature Medicine</i> , 2020, 26, 1564-1568.	15.2	71
76	4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9503-9503.	0.8	71
77	Discovering dominant tumor immune archetypes in a pan-cancer census. <i>Cell</i> , 2022, 185, 184-203.e19.	13.5	70
78	Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. <i>Oncologist</i> , 2017, 22, 823-833.	1.9	69
79	Epacadostat plus nivolumab in patients with advanced solid tumors: Preliminary phase I/II results of ECHO-204.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3003-3003.	0.8	69
80	Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 1102-1109.e1.	0.6	67
81	Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer. <i>Frontiers in Medicine</i> , 2018, 5, 351.	1.2	67
82	Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2017, 86, 296-304.	1.3	64
83	Melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 366-400.	2.3	63
84	Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 598-607.	3.2	63
85	Activated Stat-3 in Melanoma. <i>Cancer Control</i> , 2008, 15, 196-201.	0.7	62
86	Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy. <i>JCI Insight</i> , 2017, 2, .	2.3	62
87	Melanoma, Version 4.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 621-629.	2.3	61
88	Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses. <i>Cancer Immunology Research</i> , 2020, 8, 246-254.	1.6	61
89	Regulatory T cells use arginase 2 to enhance their metabolic fitness in tissues. <i>JCI Insight</i> , 2019, 4, .	2.3	60
90	The Src signaling pathway: a potential target in melanoma and other malignancies. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 91-100.	1.5	59

#	ARTICLE	IF	CITATIONS
91	Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. <i>British Journal of Cancer</i> , 2017, 116, 432-440.	2.9	59
92	Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. , 2021, 9, e002478.		59
93	Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3005-3005.	0.8	58
94	Synergistic Interaction between Histone Deacetylase and Topoisomerase II Inhibitors Is Mediated through Topoisomerase III ² . <i>Clinical Cancer Research</i> , 2005, 11, 8467-8475.	3.2	57
95	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. <i>European Journal of Cancer</i> , 2021, 144, 182-191.	1.3	57
96	Phase II Trial of Karenitecin in Patients with Malignant Melanoma: Clinical and Translational Study. <i>Clinical Cancer Research</i> , 2005, 11, 3009-3016.	3.2	56
97	Dual MEK/AKT inhibition with trametinib and <sc>GSK</sc>2141795 does not yield clinical benefit in metastatic <sc>NRAS</sc>-mutant and wild-type melanoma. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 110-114.	1.5	55
98	PD-1 and PD-L1 antibodies for melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3111-3116.	1.4	54
99	The State of Melanoma: Emergent Challenges and Opportunities. <i>Clinical Cancer Research</i> , 2021, 27, 2678-2697.	3.2	53
100	Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9504-9504.	0.8	53
101	Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. <i>Melanoma Research</i> , 2009, 19, 167-175.	0.6	52
102	Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9005-9005.	0.8	52
103	Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264-272)/HLA-A*0201 Complex, in Patients with Advanced Malignancies. <i>Clinical Cancer Research</i> , 2011, 17, 7765-7775.	3.2	49
104	A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 903-910.	1.1	48
105	Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA9000-LBA9000.	0.8	48
106	Angiotensin II: An Intraovarian Regulatory Peptide. <i>American Journal of the Medical Sciences</i> , 1988, 295, 406-408.	0.4	47
107	Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients. <i>Journal of Hematology and Oncology</i> , 2017, 10, 3.	6.9	47
108	The Liver's Immunity Nexus and Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2022, 28, 5-12.	3.2	47

#	ARTICLE	IF	CITATIONS
109	Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy. Cellular and Molecular Immunology, 2022, 19, 33-45.	4.8	47
110	A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma. Cancer Chemotherapy and Pharmacology, 2014, 73, 103-111.	1.1	45
111	Characterization of Angiotensin I-Converting Enzyme (ACE)-Containing Follicles in the Rat Ovary during the Estrous Cycle and Effects of ACE Inhibitor on Ovulation*. Endocrinology, 1990, 126, 2927-2935.	1.4	43
112	Nivolumab plus ipilimumab in the treatment of advanced melanoma. Journal of Hematology and Oncology, 2015, 8, 123.	6.9	42
113	Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12,) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.0	42
114	Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma.. Journal of Clinical Oncology, 2017, 35, 9510-9510.	0.8	42
115	The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics. Journal of Clinical Pharmacology, 2014, 54, 368-374.	1.0	41
116	Changes in Dendritic Cell Phenotype After a New High-dose Weekly Schedule of Interleukin-2 Therapy for Kidney Cancer and Melanoma. Journal of Immunotherapy, 2010, 33, 817-827.	1.2	40
117	Epacadostat plus nivolumab for advanced melanoma: Updated phase 2 results of the ECHO-204 study.. Journal of Clinical Oncology, 2018, 36, 9511-9511.	0.8	39
118	Cutaneous melanoma: A model to study cancer metastasis. Journal of Surgical Oncology, 2011, 103, 538-549.	0.8	38
119	Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. British Journal of Cancer, 2012, 106, 85-91.	2.9	38
120	Association of <i>BRAF</i> V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma. JAMA Oncology, 2020, 6, 1256.	3.4	38
121	Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Management and Research, 2010, 2, 197.	0.9	38
122	Potential Approaches for Myocardial Regeneration. Annals of the New York Academy of Sciences, 1995, 752, 446-454.	1.8	37
123	In-field and abscopal response after short-course radiation therapy in patients with metastatic Merkel cell carcinoma progressing on PD-1 checkpoint blockade: a case series. , 2018, 6, 43.		37
124	Plasmid IL-12 electroporation in melanoma. Human Vaccines and Immunotherapeutics, 2012, 8, 1734-1738.	1.4	35
125	Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade. , 2016, 4, 58.		35
126	Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. European Journal of Cancer, 2018, 91, 168-170.	1.3	33

#	ARTICLE	IF	CITATIONS
127	Increased Bioavailability of Intravenous Versus Oral CI-1033, a Pan erbB Tyrosine Kinase Inhibitor: Results of a Phase I Pharmacokinetic Study. <i>Clinical Cancer Research</i> , 2006, 12, 4645-4651.	3.2	32
128	Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 1565-1574.	1.9	32
129	Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutant Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 46-53.	3.2	32
130	Phase 1b/2 trial of ribociclib+binimetinib in metastatic <i>NRAS</i> -mutant melanoma: Safety, efficacy, and recommended phase 2 dose (RP2D).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9519-9519.	0.8	32
131	5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9516-9516.	0.8	32
132	The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced <i>BRAF</i> wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial. <i>British Journal of Cancer</i> , 2015, 112, 1326-1331.	2.9	30
133	Involution of Eruptive Melanocytic Nevi on Combination <i>BRAF</i> and <i>MEK</i> Inhibitor Therapy. <i>JAMA Dermatology</i> , 2014, 150, 1209.	2.0	28
134	The gut microbiota and immune checkpoint inhibitors. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 2178-2182.	1.4	28
135	Layilin augments integrin activation to promote antitumor immunity. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	28
136	Immunotherapy for melanoma. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2018, 37, 127-131.	1.6	28
137	A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma. <i>Annals of Oncology</i> , 2016, 27, 947-952.	0.6	24
138	Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma. <i>Immunotherapy</i> , 2016, 8, 775-784.	1.0	24
139	Immunotherapy as part of a multidisciplinary approach to melanoma treatment. <i>Frontiers in Bioscience - Landmark</i> , 2006, 11, 1.	3.0	23
140	A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, O5.	1.8	23
141	Abstract CT104: Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcome. <i>Cancer Research</i> , 2014, 74, CT104-CT104.	0.4	23
142	Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3006-3006.	0.8	23
143	Phase 1 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in patients (pts) with advanced solid tumor or lymphomas.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS3099-TPS3099.	0.8	23
144	Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon β 2b in patients with resected high-risk melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 657-666.	1.1	22

#	ARTICLE	IF	CITATIONS
145	Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma. Expert Opinion on Biological Therapy, 2012, 12, 1087-1099.	1.4	22
146	Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475.. Journal of Clinical Oncology, 2014, 32, 3015-3015.	0.8	22
147	Mouse RAD50 Has Limited Epitopic Homology to p53 and Is Expressed in the Adult Myocardium. Journal of Biological Chemistry, 1996, 271, 29255-29264.	1.6	21
148	Overall and Progression-Free Survival in Metastatic Melanoma: Analysis of a Single-Institution Database. Cancer Control, 2006, 13, 211-217.	0.7	20
149	TCR-sequencing in cancer and autoimmunity: barcodes and beyond. Trends in Immunology, 2022, 43, 180-194.	2.9	20
150	Current and Emerging Perspectives on Immunotherapy for Melanoma. Seminars in Oncology, 2015, 42, S3-S11.	0.8	19
151	The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma. Scientific Reports, 2018, 8, 10902.	1.6	19
152	Down-Regulation of Pro-Apoptotic Genes is an Early Event in the Progression of Malignant Melanoma. Annals of Surgical Oncology, 2007, 14, 1416-1423.	0.7	18
153	Tumor Fistulization Associated With Targeted Therapy. Journal of Computer Assisted Tomography, 2011, 35, 86-90.	0.5	18
154	The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date. Drugs, 2015, 75, 563-575.	4.9	18
155	A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E/K mutant advanced melanoma. Pigment Cell and Melanoma Research, 2019, 32, 603-606.	1.5	18
156	Systemic antitumor effect and clinical response in a phase 2 trial of intratumoral electroporation of plasmid interleukin-12 in patients with advanced melanoma.. Journal of Clinical Oncology, 2014, 32, 9025-9025.	0.8	18
157	Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL).. Journal of Clinical Oncology, 2015, 33, 3012-3012.	0.8	18
158	Uncommon Manifestations of Common Malignancies. Journal of Clinical Oncology, 2004, 22, 3194-3195.	0.8	17
159	Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis.. Journal of Clinical Oncology, 2014, 32, 3517-3517.	0.8	17
160	Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma. British Journal of Cancer, 2010, 103, 1548-1553.	2.9	16
161	Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. Journal of Immunotherapy, 2017, 40, 334-340.	1.2	16
162	An isolated Merkel cell carcinoma metastasis at a distant cutaneous site presenting as a second primary tumor. Journal of Cutaneous Pathology, 2011, 38, no-no.	0.7	15

#	ARTICLE	IF	CITATIONS
163	State of the science 60th anniversary review. <i>Cancer</i> , 2008, 113, 1728-1743.	2.0	14
164	Beyond BRAF in Melanoma. <i>Current Topics in Microbiology and Immunology</i> , 2010, 355, 99-117.	0.7	14
165	Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3000-3000.	0.8	14
166	Preliminary results from phase II study of combination treatment with HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIb, IIIc, or IV unresectable or metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9543-9543.	0.8	14
167	Prognostic Biomarkers for Melanoma Immunotherapy. <i>Current Oncology Reports</i> , 2020, 22, 25.	1.8	13
168	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. <i>European Journal of Cancer</i> , 2021, 157, 391-402.	1.3	13
169	Updated overall survival (OS) for BR113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with <i>BRAF</i> V600 mutation-positive (+) metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2014, 32, 9010-9010.	0.8	13
170	Removing the Unknown From the Carcinoma of Unknown Primary. <i>Journal of Clinical Oncology</i> , 2013, 31, 174-175.	0.8	12
171	Combined dabrafenib and trametinib therapy in metastatic melanoma and organ transplantation: Case report and review of the literature. <i>JAAD Case Reports</i> , 2015, 1, S23-S25.	0.4	12
172	Correlation between metastatic site and response to anti-Programmed Death-1 (PD-1) agents in melanoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9549-9549.	0.8	12
173	Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC). , 2014, 2, .		11
174	Intratumoral and Combination Therapy in Melanoma and Other Skin Cancers. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 781-796.	3.3	11
175	Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3000-3000.	0.8	11
176	Clinical characteristics predictive of response to pembrolizumab in advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9031-9031.	0.8	10
177	Future of combination therapy with dabrafenib and trametinib in metastatic melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2257-2263.	0.9	9
178	Pembrolizumab for melanoma- safety profile and future trends. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 727-729.	1.0	9
179	Treatment of Metastatic Melanoma With Leptomeningeal Disease Using Intrathecal Immunotherapy. <i>JCO Oncology Practice</i> , 2020, 16, 757-759.	1.4	9
180	A phase I trial of BKM120 combined with vemurafenib in BRAFV600^{E/k} mutant advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9101-9101.	0.8	9

#	ARTICLE	IF	CITATIONS
181	Association of immune-related thyroid disorders with pembrolizumab (pembro, MK-3475) in patients (pts) with advanced melanoma treated in KEYNOTE-001.. Journal of Clinical Oncology, 2015, 33, 9050-9050.	0.8	9
182	Abstract 2857: Metastatic site and response to pembrolizumab (anti-PD1 antibody) in melanoma. Cancer Research, 2015, 75, 2857-2857.	0.4	8
183	KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy.. Journal of Clinical Oncology, 2016, 34, 9513-9513.	0.8	8
184	Intratumoral Electroporation of Plasmid Encoded IL12 and Membrane-Anchored Anti-CD3 Increases Systemic Tumor Immunity. Molecular Cancer Research, 2022, 20, 983-995.	1.5	8
185	Intratumoral therapies and in-situ vaccination for melanoma. Human Vaccines and Immunotherapeutics, 2022, 18, 1890512.	1.4	8
186	Cutting Edge in Medical Management of Cutaneous Oncology. Seminars in Cutaneous Medicine and Surgery, 2012, 31, 140-149.	1.6	7
187	Negative but not futile: MAGE-A3 immunotherapeutic for melanoma. Lancet Oncology, The, 2018, 19, 852-853.	5.1	7
188	Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma. Annals of Surgical Oncology, 2020, 27, 4122-4130.	0.7	7
189	Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with <i>BRAF</i> V600â€“mutant unresectable or metastatic melanoma (MM).. Journal of Clinical Oncology, 2017, 35, 9505-9505.	0.8	7
190	PTCH1 Mutation in a Patient With Metastatic Undifferentiated Carcinoma With Clear Cell Change. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 778-783.	2.3	6
191	BEAM Trial: Lighting the Way Ahead?. Journal of Clinical Oncology, 2012, 30, 6-7.	0.8	5
192	Intratumoral electroporation of plasmid interleukin-12: efficacy and biomarker analyses from a phase 2 study in melanoma (OMS-I100). Journal of Translational Medicine, 2015, 13, O11.	1.8	5
193	Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapyâ€“Summary of Advances and Future Directions for Studying These Drugs. Cancer Journal (Sudbury, Mass), 2017, 23, 3-9.	1.0	5
194	Layilin Anchors Regulatory T Cells in Skin. Journal of Immunology, 2021, 207, 1763-1775.	0.4	5
195	Efficacy and safety of programmed death receptor-1 (PD-1) blockade in metastatic uveal melanoma (UM).. Journal of Clinical Oncology, 2016, 34, 9507-9507.	0.8	5
196	Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity. Molecular Therapy - Oncolytics, 2022, 25, 174-188.	2.0	5
197	Long-term overall survival from a phase I trial using intratumoral plasmid interleukin-12 with electroporation in patients with melanoma. Journal of Translational Medicine, 2015, 13, .	1.8	4
198	Pembrolizumab and Ipilimumab as Second-Line Therapy for Advanced Melanoma. Journal of Clinical Oncology, 2021, 39, 2637-2639.	0.8	4

#	ARTICLE	IF	CITATIONS
199	Abstract CT134: Intratumoral electroporation of plasmid IL-12 can prime response to anti-PD1/PD-L1 blockade in patients with Stage III/IV-M1a melanoma. <i>Cancer Research</i> , 2016, 76, CT134-CT134.	0.4	4
200	Population pharmacokinetic (popPK) model of pembrolizumab (pembro; MK-3475) in patients (pts) treated in KEYNOTE-001 and KEYNOTE-002.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3058-3058.	0.8	4
201	Model-based analysis of the relationship between pembrolizumab (MK-3475) exposure and efficacy in patients with advanced or metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3068-3068.	0.8	4
202	New drugs in gynecologic cancer. <i>Current Treatment Options in Oncology</i> , 2001, 2, 119-128.	1.3	3
203	Current immunotherapy of melanoma. <i>Clinical and Applied Immunology Reviews</i> , 2005, 5, 111-132.	0.4	3
204	Combinatorial Approach to Treatment of Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 601-612.	0.9	3
205	Metabolic tumor burden for prediction of overall survival following combined BRAF/MEK inhibition in patients with advanced BRAF mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9006-9006.	0.8	3
206	Novel T cell exhaustion marker to predict monotherapy PD-1 compared to combination CTLA-4 and PD-1 response in melanoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9520-9520.	0.8	3
207	Relationship between liver metastases and PD-1 blockade in melanoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3072-3072.	0.8	3
208	Immune monitoring outcomes of patients with stage III/IV melanoma treated with a combination of pembrolizumab and intratumoral plasmid interleukin 12 (pIL-12).. <i>Journal of Clinical Oncology</i> , 2017, 35, 78-78.	0.8	3
209	Abstract B65: Dissecting the tumor myeloid compartment reveals rare activating antigen presenting cells, critical for T cell immunity. <i>Cancer Immunology Research</i> , 2015, 3, B65-B65.	1.6	3
210	Implementation of a High-Dose Interleukin-2 Immunostimulation Biotherapy Program. <i>ICU Director</i> , 2010, 1, 77-81.	0.2	2
211	Treatment of cutaneous melanoma: current approaches and future prospects. <i>Cancer Management and Research</i> , 0, , 197.	0.9	2
212	Part I: Checkpoint inhibitors in cancer therapy. <i>Immunotherapy</i> , 2016, 8, 675-676.	1.0	2
213	Tumor response from phase II study of combination treatment with intratumoral HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIB, IIIC, or IV unresectable or metastatic melanoma. <i>Annals of Oncology</i> , 2016, 27, vi393.	0.6	2
214	Revisiting RECIST: the case of treatment beyond progression. <i>Lancet Oncology</i> , The, 2018, 19, 157-159.	5.1	2
215	Abstract CT101: Phase III study of pembrolizumab (MK-3475) versus ipilimumab in patients with ipilimumab-naive advanced melanoma. , 2015, , .		2
216	BKM120 combined with vemurafenib in vemurafenib-refractory BRAF mutant metastatic melanoma: Two cases.. <i>Journal of Clinical Oncology</i> , 2013, 31, e20010-e20010.	0.8	2

#	ARTICLE	IF	CITATIONS
217	Patient-reported outcomes (PROs) in KEYNOTE-002, a randomized study of pembrolizumab vs chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) metastatic melanoma (MEL).. Journal of Clinical Oncology, 2015, 33, 9040-9040.	0.8	2
218	Derivation and validation of a prediction scale for response to PD-1 monotherapy.. Journal of Clinical Oncology, 2016, 34, 9514-9514.	0.8	2
219	Quantitative spatial profiling of PD-1/PD-L1 interaction and HLA-DR/IDO1 to predict outcomes to anti-PD-1 in metastatic melanoma (MM).. Journal of Clinical Oncology, 2017, 35, 9517-9517.	0.8	2
220	A Review of Novel Intralesional Therapies for Melanoma, With an Emphasis on a Potential Combination Approach. Oncology, 2016, 30, 442-3.	0.4	2
221	PURIFICATION AND CHARACTERIZATION OF A NOVEL 35-kDa PROTEIN FROM TRANSFORMED CARDIOMYOCYTES. Cell Biology International, 1999, 23, 299-306.	1.4	1
222	Melanoma: Promising New Discoveries and Treatment Modalities for Difficult Clinical Scenarios. Cancer Control, 2008, 15, 192-194.	0.7	1
223	NRAS-Mutant Melanoma: Response to Chemotherapy. Archives of Dermatology, 2011, 147, 626.	1.7	1
224	Management of a Patient With Advanced BRAF-Mutant Melanoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 315-319.	2.3	1
225	Part II: Checkpoint inhibitors in cancer therapy. Immunotherapy, 2016, 8, 761-762.	1.0	1
226	Response to PD-1 Immunotherapy in Metastatic Spitzoid Carcinoma. JCO Precision Oncology, 2021, 5, 340-343.	1.5	1
227	Should Sentinel Lymph Node Biopsy Status Guide Adjuvant Radiation Therapy in Patients With Merkel Cell Carcinoma?. Advances in Radiation Oncology, 2021, 6, 100764.	0.6	1
228	Sexual activity and function in male cancer patients receiving targeted immune therapies.. Journal of Clinical Oncology, 2017, 35, e21594-e21594.	0.8	1
229	Deep profiling of tumor immune microenvironment (TME) with fluorescence activated cell sorting (FACS) in advanced melanoma.. Journal of Clinical Oncology, 2015, 33, 9012-9012.	0.8	1
230	New horizons in melanoma treatment: targeting molecular pathways. Ochsner Journal, 2010, 10, 93-8.	0.5	1
231	Melanoma: Changes below the Surface. Cancer Control, 2005, 12, 217-218.	0.7	0
232	Vascular endothelial growth factor (VEGF) inhibitors in cancer therapy: an update. Women's Oncology Review, 2006, 6, 127-136.	0.0	0
233	Reply to M.-E. Percival et al and L.B. Saltz. Journal of Clinical Oncology, 2013, 31, 2515-2516.	0.8	0
234	Efficacy of pembrolizumab (Pembro) in patients (Pts) with advanced melanoma with stable brain metastases (BM) at baseline: A pooled retrospective analysis. Annals of Oncology, 2018, 29, viii444.	0.6	0

#	ARTICLE	IF	CITATIONS
235	Current Immunotherapy of Melanoma. , 2018, , 567-576.		0
236	Combinatorial Approach to Treatment of Melanoma. , 2019, , 687-697.		0
237	ASO Author Reflections: Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma. Annals of Surgical Oncology, 2020, 27, 4131-4132.	0.7	0
238	Melanoma Genomicsâ€™Techniques and Implications for Therapy. Translational Medicine Series, 2008, , 37-54.	0.0	0
239	Protein Kinase Inhibitors. , 2011, , 319-330.		0
240	A clinical and translational phase II trial of sequential axitinib and carboplatin/paclitaxel in advanced melanoma.. Journal of Clinical Oncology, 2012, 30, 8580-8580.	0.8	0
241	Phase I study of pazopanib (PAZ) in combination with PCI-24781 (PCI) in patients (pts) with metastatic solid tumors with new tumor proliferation imaging correlates in renal cell carcinoma (RCC) and sarcoma.. Journal of Clinical Oncology, 2013, 31, TPS2623-TPS2623.	0.8	0
242	Correlation between local 18F-fluorodeoxyglucose PET/CT and T cell exhaustion for predicting treatment response in patients with advanced melanoma treated with checkpoint inhibitor mono-therapy.. Journal of Clinical Oncology, 2016, 34, 11572-11572.	0.8	0
243	Tumor intrinsic resistance to anti-programmed death 1. Translational Cancer Research, 2016, 5, S1515-S1520.	0.4	0
244	Patient attitudes toward oncofertility care in male cancer patients receiving targeted and immune therapies.. Journal of Clinical Oncology, 2017, 35, e21593-e21593.	0.8	0
245	Abstract 683A: Mechanism of liver metastasis induced systemic suppression of checkpoint inhibitor response. , 2017, , .		0
246	Combinatorial Approach to Treatment of Melanoma. , 2018, , 1-11.		0
247	Melanotic Schwannoma. AJSP Review and Reports, 2017, 22, 161-163.	0.0	0